{"id":31514,"date":"2023-03-27T21:43:25","date_gmt":"2023-03-27T19:43:25","guid":{"rendered":"https:\/\/www.transgene.com\/?p=31514"},"modified":"2025-07-23T16:41:35","modified_gmt":"2025-07-23T14:41:35","slug":"john-bell","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/john-bell\/","title":{"rendered":"John C. Bell, PhD"},"content":{"rendered":"\n<p><img decoding=\"async\" class=\"imgMembers wp-image-28055 size-medium aligncenter\" src=\"..\/..\/wp-content\/uploads\/Bell.jpg\" alt=\"\" \/><\/p>\n<p><br \/><strong>John C. Bell<\/strong>, PhD, est un expert de renomm\u00e9e internationale dans l\u2019utilisation de virus oncolytiques pour le traitement du cancer. Il a form\u00e9 et dirige le Consortium Canadien sur les Virus Oncolytiques, un groupe transcanadien multidisciplinaire qui d\u00e9veloppe des th\u00e9rapies anticanc\u00e9reuses \u00e0 base de virus. Il est le Directeur Scientifique de BioCanRx, un r\u00e9seau de centres d\u2019excellence qui d\u00e9veloppe et teste en clinique de nouvelles immunoth\u00e9rapies pour le traitement du cancer. Il a cofond\u00e9 des entreprises de biotechnologies d\u00e9veloppant des virus oncolytiques (Jennerex et Turnstone Biologics). John est Senior Scientist \u00e0 l\u2019Institut de Recherche de l\u2019H\u00f4pital d\u2019Ottawa (IRHO), un \u00e9tablissement de recherche affili\u00e9 \u00e0 l\u2019Universit\u00e9 d\u2019Ottawa. John a commenc\u00e9 sa carri\u00e8re de chercheur ind\u00e9pendant au d\u00e9partement de biochimie de l\u2019Universit\u00e9 McGill.<\/p>\n<p>Depuis 30 ans, ses programmes de recherche sont financ\u00e9s par des subventions \u00e9valu\u00e9es par des pairs. Il est l\u2019auteur de plus de 400\u00a0publications.<\/p>\n<p>Il a effectu\u00e9 ses \u00e9tudes postdoctorales au Medical Research Council \u00e0 Londres, en Angleterre, et a obtenu son doctorat en virologie et immunologie \u00e0 l\u2019Universit\u00e9 McMaster en Ontario au Canada.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>John C. Bell, PhD, est un expert de renomm\u00e9e internationale dans l\u2019utilisation de virus oncolytiques pour le traitement du cancer. Il a form\u00e9 et dirige le Consortium Canadien sur les Virus Oncolytiques, un groupe transcanadien multidisciplinaire qui d\u00e9veloppe des th\u00e9rapies anticanc\u00e9reuses \u00e0 base de virus. Il est le Directeur Scientifique de BioCanRx, un r\u00e9seau de&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/john-bell\/\">Poursuivre la lecture <span class=\"screen-reader-text\">John C. Bell, PhD<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[111],"tags":[],"class_list":["post-31514","post","type-post","status-publish","format-standard","hentry","category-outils-profils","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"John C. Bell, PhD, est un expert de renomm\u00e9e internationale dans l\u2019utilisation de virus oncolytiques pour le traitement du cancer. Il a form\u00e9 et dirige le Consortium Canadien sur les Virus Oncolytiques, un groupe transcanadien multidisciplinaire qui d\u00e9veloppe des th\u00e9rapies anticanc\u00e9reuses \u00e0 base de virus. Il est le Directeur Scientifique de BioCanRx, un r\u00e9seau de&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=31514"}],"version-history":[{"count":1,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31514\/revisions"}],"predecessor-version":[{"id":39574,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31514\/revisions\/39574"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=31514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=31514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=31514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}